Clarity assists biopharmaceutical companies around the world to develop biological therapeutics and improve the process of biopharmaceutical drug development. Our expert team helps to minimise the risks of biological drug development and enables improved efficiency and efficacy by offering its in vivo imaging services, supported by a high level of technical capabilities.

Clarity’s preclinical PET imaging services are designed for biopharmaceutical companies that wish to further characterise and de-risk their biological molecules. It allows drug developers to assess the targeting of their biological molecules early in development in vivo using PET imaging.

Clarity’s clinical research services for peptide and antibody imaging are designed for biopharmaceutical companies that wish to characterise and de-risk their biological molecules by imaging in humans. Clarity’s clinical development pathway can increase the chance of success for a therapy by using a companion diagnostic, based on peptide or antibody imaging, for clinical research.